Drug Profile
Research programme: mitochondrial protein modulators - Epirium Bio
Latest Information Update: 28 Feb 2020
Price :
$50
*
At a glance
- Originator Cardero Therapeutics
- Developer Epirium Bio; Sphaera Pharma
- Class Small molecules
- Mechanism of Action Mitochondrial protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Neuromuscular disorders
- No development reported Cerebrovascular disorders; Metabolic disorders